MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Stemline Therapeutics Company Profile (NASDAQ:STML)

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $38.25 (346.32% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetActions
4/27/2015HC WainwrightInitiated CoverageBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2015Jefferies GroupInitiated CoverageBuy$50.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015WedbushSet Price TargetBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2015Roth CapitalLower Price TargetBuy$62.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/23/2015Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2014Jefferies GroupLower Price TargetBuy$60.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2014Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2014WBB SecuritiesInitiated CoverageSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/14/2013Roth CapitalBoost Price TargetBuy$50.00 -> $55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2013AegisReiterated RatingBuy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2013AegisBoost Price TargetBuy$40.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/11/2013WedbushInitiated CoverageOutperform$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/4/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha